Bladder cancer: a disease ripe for major advances
- PMID: 25674841
Bladder cancer: a disease ripe for major advances
Abstract
Despite high incidence rates and substantial financial burdens associated with the care of patients with bladder cancer, progress in bladder cancer management has been modest and no new therapeutic agents for bladder cancer have been approved over the past decades. Fortunately, a substantial improvement in our understanding of the biology of this disease has occurred owing to revolutionizing molecular analysis platforms and increased interest among physicians and scientists in bladder cancer. As a consequence, a number of promising novel therapeutic agents are in development and are expected to make their way into clinics in the near future. This review focuses on the unique aspects of current bladder cancer research that support the assertion that bladder cancer is a likely frontier for major advancements soon.
Similar articles
-
Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.Immunotherapy. 2017 Mar;9(5):451-460. doi: 10.2217/imt-2017-0007. Immunotherapy. 2017. PMID: 28357911 Review.
-
Genetic and epigenetic aspects of bladder cancer.J Cell Biochem. 2005 May 1;95(1):24-33. doi: 10.1002/jcb.20412. J Cell Biochem. 2005. PMID: 15759278 Review.
-
Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer.Future Oncol. 2016 Dec;12(23):2673-2682. doi: 10.2217/fon-2016-0284. Epub 2016 Sep 9. Future Oncol. 2016. PMID: 27609194 Review.
-
[Animal experiment aspects of bladder cancer].Urologe A. 1991 May;30(3):172-9. Urologe A. 1991. PMID: 1871936 Review. German.
-
Endpoints of clinical trials for muscle-invasive bladder cancer.Prog Clin Biol Res. 1990;353:65-74. Prog Clin Biol Res. 1990. PMID: 2217428 Review. No abstract available.
Cited by
-
Patient-centered development of a bladder cancer survivorship care plan.Support Care Cancer. 2024 May 31;32(6):397. doi: 10.1007/s00520-024-08588-y. Support Care Cancer. 2024. PMID: 38819504
-
Comparative oncology: overcoming human cancer through companion animal studies.Exp Mol Med. 2023 Apr;55(4):725-734. doi: 10.1038/s12276-023-00977-3. Epub 2023 Apr 3. Exp Mol Med. 2023. PMID: 37009802 Free PMC article. Review.
-
Beyond the Lab: What We Can Learn about Cancer from Wild and Domestic Animals.Cancers (Basel). 2022 Dec 14;14(24):6177. doi: 10.3390/cancers14246177. Cancers (Basel). 2022. PMID: 36551658 Free PMC article. Review.
-
Deep Genomic Sequencing of Bladder Urothelial Carcinoma in Southern Chinese Patients: A Single-Center Study.Front Oncol. 2021 May 14;11:538927. doi: 10.3389/fonc.2021.538927. eCollection 2021. Front Oncol. 2021. PMID: 34055593 Free PMC article.
-
N-glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas.Cancer Med. 2021 Feb;10(4):1297-1313. doi: 10.1002/cam4.3727. Epub 2021 Jan 16. Cancer Med. 2021. PMID: 33455069 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous